GLP-1 receptor agonists and risk of hepatocellular carcinoma and all-cause mortality in patients with MASLD and type 2 diabetes: a propensity score–matched population-based cohort study

GLP-1 receptor agonist use is associated with a 64% lower risk of developing hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus.

• Use of GLP-1 receptor agonists was linked to a reduced risk of hepatocellular carcinoma (HCC) in a retrospective cohort study.
• The study included 152,329 patients diagnosed with both metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus.
• GLP-1 receptor agonist use was also associated with a significant reduction in all-cause mortality.
• Adjusted hazard ratios indicated a 0.64 risk for HCC and a 0.37 risk for all-cause mortality among users compared to non-users.
• Robustness of these findings was supported by various subgroup and sensitivity analyses.

AI simplified